➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Medtronic
Boehringer Ingelheim
McKinsey
Express Scripts

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOMETA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Zometa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00022087 ↗ Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer Completed National Cancer Institute (NCI) Phase 3 2001-12-01 RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00022087 ↗ Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer Completed Alliance for Clinical Trials in Oncology Phase 3 2001-12-01 RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
NCT00029224 ↗ Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed Novartis Phase 4 2001-10-01 Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zometa

Condition Name

Condition Name for Zometa
Intervention Trials
Breast Cancer 14
Prostate Cancer 11
Osteoporosis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zometa
Intervention Trials
Breast Neoplasms 20
Neoplasm Metastasis 17
Prostatic Neoplasms 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zometa

Trials by Country

Trials by Country for Zometa
Location Trials
United States 146
Canada 7
China 6
United Kingdom 4
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zometa
Location Trials
Wisconsin 8
California 7
Texas 7
New York 7
Missouri 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zometa

Clinical Trial Phase

Clinical Trial Phase for Zometa
Clinical Trial Phase Trials
Phase 4 6
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zometa
Clinical Trial Phase Trials
Completed 42
Terminated 11
Recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zometa

Sponsor Name

Sponsor Name for Zometa
Sponsor Trials
Novartis 12
Novartis Pharmaceuticals 11
National Cancer Institute (NCI) 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zometa
Sponsor Trials
Other 72
Industry 39
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKinsey
McKesson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.